Overview

This trial is active, not recruiting.

Condition head and neck cancer
Treatments celecoxib, microarray analysis, protein expression analysis, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
Phase phase 1/phase 2
Sponsor Centre Hospitalier Universitaire Vaudois
Start date June 2006
Trial size 24 participants
Trial identifier NCT00357617, CDR0000490047, CHUV-CEPO-161-05, EU-20627

Summary

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving celecoxib before surgery may reduce the amount of normal tissue that needs to be removed. Collecting and storing samples of tumor tissue, blood, and urine from patients with head and neck cancer to study in the laboratory may help doctors learn more about the cancer and predict how well patients will respond to treatment with celecoxib.

PURPOSE: This phase I/II trial is studying changes in tumor cells and how well celecoxib works in treating patients with head and neck cancer that can be removed by surgery.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Masking open label
Primary purpose treatment

Primary Outcomes

Measure
Molecular markers of angiogenesis in tumor tissues (PGE2, VEGF, MMP-9, sFlt-1, ERK phosphorylation, PKB phosphorylation, and ErbB2 levels)
time frame:

Secondary Outcomes

Measure
Molecular markers in plasma (VEGF, MMP-9, and sFlt1)
time frame:
Molecular marker in urine (PGE2)
time frame:
Apoptosis/proliferation in tumor cells and endothelial cells
time frame:
Gene expression profiling in fresh tumor tissues (Erb-B2, c-IAP-2, PAI-1, MAPK-4, integrin α V, N-CAM, caspase 6, ErbB2 transducer, angiopoietin like-2, interleukin-8, and MMP13)
time frame:
Tumor perfusion imaging by perfusion CT scan
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed or high clinical suspicion of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx - No carcinoma of sinonasal or nasopharynx - Clinical stage T1-4, N0-2, M0 disease - Tumor must be considered resectable with planned surgical excision - No lymph nodes > 6 cm (N3) - No distant metastasis PATIENT CHARACTERISTICS: - Absolute neutrophil count ≥ 1,500/mm³ - Platelet count ≥ 100,000/mm³ - Hemoglobin ≥ 10 g/dL - Creatinine ≤ 1.5 times upper limit of normal (ULN) - Creatinine clearance ≥ 60 mL/min - AST and ALT ≤ 2.5 times ULN - Bilirubin normal - History of prior malignancy allowed if there is no evidence of recurrence or metastases at the time of screening - No comorbidity that precludes operability - No known liver impairment - Known recent gastric or duodenal ulcer allowed if treated for > 6 weeks prior to study enrollment - No known hypersensitivity to celecoxib - No known allergic reactions to sulfonamides, aspirin, or other NSAIDs - No psychological, familial, sociological, or geographical condition that would interfere with study compliance and follow-up schedule - Not pregnant or nursing - Negative pregnancy test PRIOR CONCURRENT THERAPY: - More than 2 months since prior and no other concurrent anticancer or investigational drugs - More than 2 weeks since prior and no other concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids - No prior radiotherapy to the head and neck region - No concurrent radiotherapy - No concurrent therapeutic anticoagulation - No concurrent administration of any of the following: - Other cyclooxygenase-2 inhibitors - Aspirin - Low-dose aspirin for cardiovascular prophylaxis allowed - Aluminum and magnesium-containing antacids - ACE inhibitors - Furosemide - Known inhibitors of P450 2C9 (e.g., fluconazole, fluoxetine, fluvoxamin, isoniazid, omeprazole) - Known inducers of P450 2C9 (e.g., rifampin) - Lithium - Acenocoumarol

Additional Information

Official title Evaluation of the Effect of Celecoxib on Angiogenesis Markers in Patients With Operable Head and Neck Squamous Cell Carcinoma
Description OBJECTIVES: Primary - Evaluate the changes in molecular markers of angiogenesis before and after treatment with celecoxib in tumor tissues of patients with resectable head and neck squamous cell carcinoma. Secondary - Evaluate the changes in molecular markers of angiogenesis before and after treatment with celecoxib in blood tissues of these patients. - Evaluate the effects of celecoxib on indirect measures of tumor perfusion, as measured by perfusion CT scan, in these patients. - Evaluate the effects of celecoxib on apoptosis and proliferation rate on tumor cells and on endothelial cells in these patients. - Identify potential new markers of the activity of cyclooxygenase-2 inhibitors and identify new pathways of potential interests by performing gene expression profiling of tumor tissues before and after exposure to celecoxib. OUTLINE: This is an open-label, nonrandomized, uncontrolled study. Patients undergo panendoscopy and tumor biopsy on day 0. Patients receive oral celecoxib twice daily beginning on day 1 and continuing for at least 14 days*. Patients then undergo definitive surgery. NOTE: *Treatment continues until the day before surgery. Tumor, blood, and urine samples are collected at baseline and periodically during study. Tumor quantification by perfusion CT scan is performed at baseline and after treatment with celecoxib. Biological markers are detected by immunohistochemistry and enzyme immunoassay. Blood vascular density, apoptosis, proliferation, and endothelial cell:tumor ratio are measured by indirect hemagglutination. Gene expression is measured by microarray analysis. After surgery, patients are followed at 4 weeks and then periodically thereafter. PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in December 2010.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).